Bayesian statistics in oncology
- 19 November 2009
- Vol. 115 (23), 5371-5381
- https://doi.org/10.1002/cncr.24628
Abstract
The rise of evidence‐based medicine as well as important progress in statistical methods and computational power have led to a second birth of the >200‐year‐old Bayesian framework. The use of Bayesian techniques, in particular in the design and interpretation of clinical trials, offers several substantial advantages over the classical statistical approach. First, in contrast to classical statistics, Bayesian analysis allows a direct statement regarding the probability that a treatment was beneficial. Second, Bayesian statistics allow the researcher to incorporate any prior information in the analysis of the experimental results. Third, Bayesian methods can efficiently handle complex statistical models, which are suited for advanced clinical trial designs. Finally, Bayesian statistics encourage a thorough consideration and presentation of the assumptions underlying an analysis, which enables the reader to fully appraise the authors' conclusions. Both Bayesian and classical statistics have their respective strengths and limitations and should be viewed as being complementary to each other; we do not attempt to make a head‐to‐head comparison, as this is beyond the scope of the present review. Rather, the objective of the present article is to provide a nonmathematical, reader‐friendly overview of the current practice of Bayesian statistics coupled with numerous intuitive examples from the field of oncology. It is hoped that this educational review will be a useful resource to the oncologist and result in a better understanding of the scope, strengths, and limitations of the Bayesian approach. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 45 references indexed in Scilit:
- Prioritizing Climate Change Adaptation Needs for Food Security in 2030Science, 2008
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Recent developments in meta‐analysisStatistics in Medicine, 2007
- Designing Dose-Escalation Trials With Late-Onset Toxicities Using the Time-to-Event Continual Reassessment MethodJournal of Clinical Oncology, 2006
- When did Bayesian inference become "Bayesian"?Bayesian Analysis, 2006
- Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancerBritish Journal of Surgery, 2005
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- Interpreting statistics in medical literature: A vade mecum for surgeonsJournal of the American College of Surgeons, 2004
- Bayeswatch: an overview of Bayesian statisticsJournal of Evaluation in Clinical Practice, 2002
- Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trialRadiotherapy and Oncology, 1999